Breaking News Instant updates and real-time market news.

CELG

Celgene

$98.63

0.21 (0.21%)

16:33
09/12/19
09/12
16:33
09/12/19
16:33

Celgene announces phase 3 study results of CC-486 in newly diagnosed AML

Celgene announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia, or AML, who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy. The study demonstrated that maintenance treatment with CC-486 resulted in a highly statistically significant and clinically meaningful improvement in overall survival compared to placebo. The key secondary endpoint of relapse-free survival also showed a statistically significant improvement. CC-486 was well-tolerated and there were no unexpected safety events in QUAZAR AML-001. This phase 3 study enrolled 472 patients, randomized 1:1 to receive either oral CC-486 300mg or placebo once daily for 14 days of a 28-day cycle plus best supportive care until disease relapse. Data from QUAZAR AML-001 will be submitted to a future medical meeting. Celgene also plans regulatory submissions for CC-486 beginning in the first half of 2020.

  • 27

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

CELG Celgene
$98.63

0.21 (0.21%)

08/26/19
PIPR
08/26/19
NO CHANGE
PIPR
Amgen price target raised to $218 from $210 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond maintained an Overweight rating on Amgen (AMGN) and raised his price target on shares to $218 from $210 after Amgen announced it would acquire worldwide rights to Celgene's (CELG) Otelza for $13.4B in cash. Raymond said in a research note titled "Oh Otezla! Logical Deal Bolsters Commercial Footprint Meaningfully" that the deal "makes logical sense," and while "some may quibble with the price," the deal is highly accretive as it stands and adds "significant positive" net present value. The analyst concluded that the acquisition added around $8 per share to his sum of parts analysis of Amgen.
08/27/19
RBCM
08/27/19
NO CHANGE
Target $206
RBCM
Sector Perform
Amgen price target raised to $206 from $192 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Amgen to $206, saying that despite the "sticker shock" of its $13.4B deal for the Otezla franchise, the transaction is expected to be immediately accretive to earnings and fitting well with its existing inflammation and immunology portfolio. The analyst believes that Amgen should be able to grow revenue "majorly" over the next 3 years as it leverages Otezla potential with its legal victory on Enbrel, stating that there is a case for its multiple to re-rate higher. MacKay keeps his Sector Perform rating on Amgen shares as he awaits for its emerging pipeline to also "fill the shoes" of its maturing assets.
08/27/19
WELS
08/27/19
NO CHANGE
Target $220
WELS
Market Perform
Amgen price target raised to $220 from $202 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Amgen (AMGN) to $220 from $202 following the proposed acquisition of worldwide rights to OTEZLA from Celgene (CELG). While the proposed acquisition would be immediately accretive in 2020, he believes current valuation fairly contemplates future growth and that long-term value from OTEZLA should be considered in the context of potential earlier challenges to its intellectual property. The analyst reiterates a Market Perform rating on Amgen's shares.
08/27/19
OPCO
08/27/19
NO CHANGE
Target $240
OPCO
Outperform
Amgen price target raised to $240 from $230 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $240 from $230 after the company announced plans to acquire Celgene's (CELG) Otezla for $13.4B or $11.2B net of tax benefits in an immediately accretive transaction that should close by the end of 2019 assuming certain conditions are met. The analyst is encouraged by the strategic rationale and potential operating leverage behind adding Otezla to a leading auto-immune portfolio bolstering the financial profile of Amgen that is already supported by recent new product launches and a burgeoning pipeline. Olson reiterates an Outperform rating on Amgen's shares.

TODAY'S FREE FLY STORIES

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:49
10/13/19
10/13
19:49
10/13/19
19:49
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

FB

Facebook

$184.20

4.02 (2.23%)

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

TGT

Target

$111.86

1.29 (1.17%)

T

AT&T

$37.58

0.17 (0.45%)

ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

NUE

Nucor

$52.69

2.48 (4.94%)

PNR

Pentair

$37.33

1.215 (3.36%)

GWW

Grainger

$305.24

16.49 (5.71%)

K

Kellogg

$62.14

-0.27 (-0.43%)

ATVI

Activision Blizzard

$54.80

1.1 (2.05%)

TTWO

Take-Two

$122.42

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 18

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

IGMS

IGM Biosciences

$17.53

-0.125 (-0.71%)

19:42
10/13/19
10/13
19:42
10/13/19
19:42
Initiation
IGM Biosciences initiated  »

IGM Biosciences initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

19:37
10/13/19
10/13
19:37
10/13/19
19:37
Hot Stocks
LeMaitre acquires biologic patch business from Admedus »

LeMaitre Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

18:37
10/13/19
10/13
18:37
10/13/19
18:37
Periodicals
SoftBank seeking control of WeWork through financing package, WSJ says »

SoftBank (SFTBY) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KOD

Kodiak Sciences

$18.24

1.34 (7.93%)

18:34
10/13/19
10/13
18:34
10/13/19
18:34
Hot Stocks
Kodiak Sciences announces safety, efficacy from Phase 1b study of KSI-301 »

Kodiak Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:29
10/13/19
10/13
18:29
10/13/19
18:29
Recommendations
Adverum Biotechnologies analyst commentary at Piper Jaffray »

Adverum '022 looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:23
10/13/19
10/13
18:23
10/13/19
18:23
Hot Stocks
Adverum Biotechnologies reports additional data from Phase 1 trial of ADVM-022 »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$56.41

0.55 (0.98%)

18:03
10/13/19
10/13
18:03
10/13/19
18:03
Hot Stocks
ConocoPhillips announces $1.39B agreement to sell interests in Australia-West »

ConocoPhillips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.58

0.17 (0.45%)

, CMCSA

Comcast

$45.53

1.02 (2.29%)

17:18
10/13/19
10/13
17:18
10/13/19
17:18
On The Fly
Box Office Battle: 'Joker' stays at number 1 with another $55M »

"Box Office Battle" is…

T

AT&T

$37.58

0.17 (0.45%)

CMCSA

Comcast

$45.53

1.02 (2.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$58.16

0.83 (1.45%)

LGF.A

Lionsgate

$9.52

0.22 (2.37%)

LGF.B

Lionsgate

$8.97

0.19 (2.16%)

DIS

Disney

$130.08

0.73 (0.56%)

VIAB

Viacom

$23.02

0.505 (2.24%)

VIA

Viacom

$25.45

0.65 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

PCG

PG&E

$8.08

0.3 (3.86%)

16:48
10/13/19
10/13
16:48
10/13/19
16:48
Periodicals
PG&E turns down San Francisco's $2.5B offer to acquire assets, Reuters says »

PG&E rejected a $2.5B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

TTGT

TechTarget

$22.64

0.14 (0.62%)

, SKHCY

Sonic Healthcare

$0.00

(0.00%)

16:44
10/13/19
10/13
16:44
10/13/19
16:44
Conference/Events
Commvault to hold a conference »

Commvault GO 2019 will be…

TTGT

TechTarget

$22.64

0.14 (0.62%)

SKHCY

Sonic Healthcare

$0.00

(0.00%)

NTAP

NetApp

$51.50

1.74 (3.50%)

HPE

HP Enterprise

$14.35

0.24 (1.70%)

HLF

Herbalife Nutrition

$39.07

0.51 (1.32%)

FORR

Forrester

$32.43

0.61 (1.92%)

CSCO

Cisco

$46.52

0.38 (0.82%)

CVLT

Commvault

$45.51

0.695 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 29

    Oct

  • 29

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 12

    Dec

FB

Facebook

$184.20

4.02 (2.23%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Periodicals
Warren buying Facebook ads claiming Zuckerberg backs Trump, Bloomberg says »

Elizabeth Warren is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

KBH

KB Home

$33.92

-0.15 (-0.44%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Conference/Events
SunTrust to hold a field trip »

Field Trip with KB Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

BX

Blackstone

$47.10

0.62 (1.33%)

16:34
10/13/19
10/13
16:34
10/13/19
16:34
Periodicals
Blackstone discussed with Citadel about buying stake, WSJ reports »

Blackstone has held talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

16:29
10/13/19
10/13
16:29
10/13/19
16:29
Periodicals
Google bars high-interest consumer loan services from app store, WSJ reports »

Google has barred…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

16:28
10/13/19
10/13
16:28
10/13/19
16:28
General news
Trump working with Congress on 'powerful' Turkey sanctions »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23
Hot Stocks
Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies »

Allergan and Molecular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$39.49

1.8 (4.78%)

, UBER

Uber

$30.09

1.19 (4.12%)

16:04
10/13/19
10/13
16:04
10/13/19
16:04
Periodicals
Lyft sues NYC over cruising time caps, Reuters reports »

Following its rival…

LYFT

Lyft

$39.49

1.8 (4.78%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

GM

General Motors

$35.57

0.9 (2.60%)

15:59
10/13/19
10/13
15:59
10/13/19
15:59
Periodicals
UAW boosting strike pay as General Motor walkout continues, Reuters says »

The United Auto Workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49
Periodicals
Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says »

Health authorities in…

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

HMTV

Hemisphere Media

$11.70

0.05 (0.43%)

15:48
10/13/19
10/13
15:48
10/13/19
15:48
Initiation
Hemisphere Media initiated at Wells Fargo »

Hemisphere Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37
Hot Stocks
Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD »

Pfizer announced complete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

CNCE

Concert Pharmaceuticals

$5.85

(0.00%)

15:29
10/13/19
10/13
15:29
10/13/19
15:29
Hot Stocks
Concert Pharmaceuticals presents Phase 2 data in Alopecia Areata »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$76.14

0.38 (0.50%)

15:23
10/13/19
10/13
15:23
10/13/19
15:23
Hot Stocks
Incyte announces 52-week results from Phase 2 study of Ruxolitinib cream »

Incyte announced 52-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

LLY

Eli Lilly

$108.37

1.54 (1.44%)

14:15
10/13/19
10/13
14:15
10/13/19
14:15
Hot Stocks
Eli Lilly says Taltz met co-primary endpoints in Phase 3 plaque psoriasis study »

Eli Lilly announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.